# CD5, an Undercover Regulator of TCR Signaling

Guillaume Voisinne, Anne Gonzalez De Peredo, Romain Roncagalli

► To cite this version:

Guillaume Voisinne, Anne Gonzalez De Peredo, Romain Roncagalli. CD5, an Undercover Regulator of TCR Signaling. Frontiers in Immunology, 2018, 9, 10.3389/fimmu.2018.02900. [hal-02089002](https://hal.science/hal-02089002)

HAL Id: hal-02089002

https://hal.science/hal-02089002

Submitted on 26 Nov 2019

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Check for
updates

# CD5, an Undercover Regulator of TCR Signaling

Guillaume Voisinne¹, Anne Gonzalez de Peredo² and Romain Roncagalli¹*

¹Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, INSERM, CNRS, Marseille, France, ²Institut de Pharmacologie et de Biologie Structurale, Département Biologie Structural Biophysique, Protéomique Génopole Toulouse Midi Pyrénées CNRS UMR 5089, Toulouse, France

T cells are critical components of adaptive immunity. As such, their activation is regulated by the T cell receptor (TCR) that constantly scan peptides associated with major histocompatibility complexes (MHC). TCR engagement initiates a series of molecular events leading to cytokine secretion, proliferation, and differentiation of T cells. As a second coincident event, activation of co-stimulatory molecules, such as CD28, synergize with the TCR in order to prolong and/or amplify intracellular signals. With the recent advances in immunotherapies targeting T cells, co-inhibitory receptors are of growing interest for immunologists due to their potential modulatory properties on T cell functions. However, special attention should be dedicated to avoid unwanted clinical outcomes (1). In particular, Manichean categorization of receptors based on incomplete functional knowledge can lead to an over-simplistic view of complex cellular regulations. Thus, analysis of the functions that characterize these receptors in diverse physiological contexts remains essential for their rational use in therapeutic protocols. Here we focus on CD5, a transmembrane receptor that regulates T cell functions and development but remains poorly characterized at the molecular level. We will review its roles in physiological conditions and suggest potential molecular effectors that could account for CD5-dependent regulation of TCR signaling.

**Keywords:** CD5, TCR-T cell receptor, signaling/signaling pathways, coreceptor, inhibition

## REGULATION OF T CELL DEVELOPMENT AND FUNCTION BY CD5

Seminal studies have identified CD5 as an activation marker of T cells (2, 3). Thus, expression of CD5 increases according to the magnitude of the signal delivered by the TCR. Consequently, CD5 expression reflects the heterogeneity of the signal strength associated with each individual TCR within a polyclonal T cell population. This observation has been also documented with various TCR transgenic mice, for which CD5 expression levels correlated with the affinity of the TCR with its known agonist peptide (4, 5). The study of CD5 deficient mice allowed to position CD5 not only as an activation marker but also as an active player of the TCR signaling pathway (6). Indeed, absence of CD5 enhanced signaling and activation of double positive (DP) thymocytes induced by TCR stimulation. Moreover, CD5 deficient DP thymocytes from TCR transgenic mice have a shifted windows of selection toward a lower threshold, resulting in an enhanced positive or negative selection with TCRs of low or high avidities, respectively (7, 8). These results established CD5 as a negative regulator of the TCR signaling pathway in immature thymocytes.

**OPEN ACCESS**

**Edited by:**
Alexandre M. Carmo,
i3S, Instituto de Investigação e
Inovação em Saúde, Portugal

**Reviewed by:**
Nicole L. La Gruta,
Monash University, Australia
Georges Bismuth,
INSERM U1016 Institut Cochin,
France

*Correspondence:
Romain Roncagalli
roncagalli@ciml.univ-mrs.fr

**Specialty section:**
This article was submitted to
*T Cell Biology,*
a section of the journal
Frontiers in Immunology

**Received:** 15 August 2018
**Accepted:** 26 November 2018
**Published:** 07 December 2018

**Citation:**
Voisinne G, Gonzalez de Peredo A and Roncagalli R (2018) CD5, an Undercover Regulator of TCR Signaling. Front. Immunol. 9:2900. doi: 10.3389/fimmu.2018.02900
In contrast to its role in the thymus, the functions of CD5 in the periphery remain unclear. On the one hand CD5 deficient peripheral T cells showed better proliferative responses following TCR stimulation than their wild-type counterparts (8), suggesting that CD5 also acts as a negative regulator of TCR signaling in mature T cells. On the other hand, analysis of polyclonal and TCR transgenic T cells showed that effector functions of mature T cells positively correlate with CD5 expression (4, 5, 9). As a result, it has been proposed that the abundance of CD5 can predict TCR avidities with self and foreign peptides (4). Also, other reports suggested that CD5<sup>hi</sup> cells acquired intrinsic properties during thymic selection against self-peptides that could be maintained in periphery leading to improved reactivity against foreign antigens (5, 9).

These complex results illustrate the difficulty of assessing the impact of altered thymic selection on T cell reactivity in the periphery. Indeed, comparing results obtained in the periphery and in the thymus raises several issues. The first issue is that phenotypic differences observed in peripheral T cells could result from perturbed thymocyte education. Hence, in the case of CD5 deficient mice, the increased proliferation observed in periphery could be due to an alteration of the TCR repertoire selected during thymic development. Also, changes in selection pressure could modify the abundance of other regulators of the TCR signaling pathway. For example, it has been shown that the abundance of CD6 (a transmembrane receptor structurally related to CD5) was higher in peripheral T cells deficient for CD5 (10). The second issue is related to the difficulty of tracking the same cell during the processes of thymic selection and egression *in vivo*. Thus, although CD5 expression correlates with the magnitude of the TCR signal during DP selection and of tonic TCR signals in periphery, it does not necessarily indicate that a CD5<sup>hi</sup> cell in the thymus remains CD5<sup>hi</sup> in the periphery. Indeed, it is possible that selecting self-peptides are absent in the periphery or do not induce a similar TCR reactivity as they did during thymocyte selection. The above issues make it difficult to distinguish between direct CD5 signaling effects in peripheral T cells from indirect consequences of perturbed thymic selection. Conditional deletion of CD5 in peripheral T cells would greatly help elucidate the role of CD5 in periphery independently of its effect on thymic selection.

## STRUCTURAL BASIS FOR THE NEGATIVE REGULATION EXERTED BY CD5

From a structural point of view, CD5 is a type-I transmembrane glycoprotein with an extracellular region composed of three scavenger receptor cysteine-rich (SRCR) domains. Several CD5 ligands have been reported such as CD72, the IgV(H) framework region and several polypeptides (gp40-80, gp150) whose identity remains undetermined (3, 11, 12). CD5 can also establish low stoichiometric homophilic interactions in cis or in trans (13). Whether these molecules bind to CD5 and modulate its activity in physiological settings remains a matter of debate. Even so, it has been reported that

cross-linking of antibodies targeting the extracellular domain of CD5 induces signaling in the Jurkat cell line (14). In the absence of binding of CD5 with potential ligands, TCR stimulation triggers CD5 phosphorylation on tyrosine residues (15) and its translocation into the immunological synapse (16), thereby indicating a direct regulation of CD5 by TCR signals. Both types of stimulation suggest that CD5-mediated signaling inhibition could be potentiated by spatial confinement in areas where phosphatases are excluded and kinases enriched.

On its cytoplasmic tail, CD5 contains four tyrosine residues at position 402, 453, 464, and 486 in human (historically Y378, Y429, Y441, and Y463 if the signal peptide sequence is not included) exposed to potential phosphorylation regulations. Although the tyrosine Y402 was initially associated with the CD5 inhibitory signal through its association with the SH2 domain containing-tyrosine phosphatase 1 (SHP-1) (17), cumulative data from mass spectrometry analysis failed to detect phosphorylation at this position even though the corresponding peptide bearing this tyrosine residue is frequently observed (source: phosphosite.org and peptideatlas.org). In contrast, the three distal tyrosine residues (Y453, Y464, and Y486) have been frequently observed in their phosphorylated form. Moreover, studies using either phosphopeptides coding for CD5 tyrosine motifs or B cells transfected with a chimeric molecule composed of the extracellular and the transmembrane domains of FcgRIIB with the cytoplasmic domain of CD5 did not detect SHP-1 interaction (18, 19). Consistently, analysis of truncated mutants of CD5 demonstrated that the cytoplasmic tail of CD5 comprising these three distal tyrosines residues could account for global CD5 phosphorylation following pervanadate stimulation and was required for CD5 signaling activity (7). These three distal tyrosine residues are subjected to Src kinases regulation and have been proposed as docking sites for several effectors such as the RasGAP or the phosphatidylinositol 3-kinase (PI3K) (18, 20). In addition to the tyrosine dependent interactions, it has been shown that the two carboxy-terminal serine residues of CD5 allow constitutive binding with the casein kinase 2 (CK2) (21). Transgenic mouse models for which the CD5 serine motif has been deleted display abnormal T cell development and perturbed differentiation of mature T cells (22, 23). Moreover, T cells from these mice exhibit reduced survival capacity and hypoproliferate in response to TCR stimulation. These studies illustrate that CD5 signal transduction relies on both tyrosine and serine motifs.

More recently, our group demonstrated that CD5 could associate with CBL, CBLB, and GRB2 in mature CD4<sup>+</sup> T cells upon TCR stimulation (24, 25). To do so, we developed mouse models suitable for proteomics analysis in primary T lymphocytes. These mice are genetically engineered to express proteins bearing an OST tag at their N terminal, thereby serving as "baits" allowing affinity purification (AP) of protein complexes. AP samples are subjected to tandem mass spectrometry (MS-MS) and specific binding partners are identified by comparing protein intensities in samples from cells bearing the endogenous or the OST-tagged proteins. Using this approach, the set
of specific binding partners for a protein of interest, its "interactome," can be quantified in a comprehensive manner. We discuss in the following how the molecular mechanisms of CD5 signaling might be revisited in light of these recent results.

## COOPERATIVITY BETWEEN CD5 AND THE UBIQUITIN LIGASES CBL AND CBLB IN MATURE T CELLS

CBL molecules (CBL and CBLB) are E3-ubiquitin ligases involved in the negative regulation of the TCR signaling pathway via different complementary mechanisms (26). CBL has been shown to control ubiquitination and degradation of the CD3 chains and activities of the proximal tyrosine kinases LCK and ZAP70 (27–29) whereas CBLB negatively regulates the CD28 co-stimulatory pathway by dampening the PI3K activity (30–32).

CBL and CBLB both target specific substrates for ubiquitination. Globally, CBLB proximal molecular environment contains more ubiquitinated species than CBL, suggesting a predominant role of CBLB over CBL for this post-translational regulation in mature T cell (24). This observation correlated with the severe phenotype of the Cbl-b⁻/⁻ T cells exhibiting an increased capacity to proliferate and secrete cytokines when activated (30, 31).

Because CBL and CBLB interact together (24, 33) (Figure 1), it is possible that the scaffolding property of each ubiquitin ligase allows trans-ubiquitination of contiguous proteins not subjected to cis-ubiquitination. For example, although PI3K subunits are specifically associated with CBL in peripheral T cells, their ubiquitination is mainly regulated by CBLB (24, 32).

In peripheral T cells, both CBL and CBLB associated with CD5 upon TCR stimulation (24). This suggests that CD5 could play a scaffolding role, facilitating the CBL-CBLB relocalization to the plasma membrane in proximity of the tyrosine kinases required for their activities. This cooperativity between CBL, CBLB, and CD5 could also be important for enhancing ubiquitination within supra molecular complexes assembled upon TCR stimulation. In line with this model, mature T cell from CD5 deficient mouse showed reduced CBL-dependent ubiquitination in activated T cells (24). More specifically, ubiquitination of PI3K subunits following TCR stimulation was reduced in the absence of CD5 suggesting that CD5 could facilitate trans-ubiquitination.

In the CBLB deficient T cells, association of CD5 with CBL was preserved. Interestingly, the absence of CBLB enhanced the interaction between CD5 and CBL and increased global protein ubiquitination within the complex formed around CBL (24). These results suggest that CBL molecules compete for binding to shared docking sites on CD5 and in the ubiquitination of shared substrates. Also, they indicate that despite a molecular reorganization in the absence of CBLB, CBL is unable to fully compensate for CBLB deficiency in mature T cells. Hence, in peripheral T cells, CD5 could negatively control TCR signaling by coordinating ubiquitination through its interaction with CBL and CBLB.

## INTERACTIONS BETWEEN CD5 AND CBL IN THYMOCYTES

The situation described above is modified in thymocytes where abundances of CBL molecules differ from that in mature T cells. While CBL and CBLB have similar abundances in peripheral T cells, protein expression of CBLB is much lower than CBL in thymocytes (24). In agreement with observations reported in CBLB deficient mature T cells, analysis of the CBL interactome in thymocytes revealed that the association between CD5 and CBL is maintained despite the low abundance of CBLB (Figure 1). These results suggest the existence of a functional relationship between CBL and CD5 in thymocytes. The comparison of the phenotypes between the CBL and CD5 deficient mice partially supports this hypothesis. Indeed, both CBL and CD5 deficient DP thymocytes show enhanced intracellular signaling which, onto a low avidity TCR transgenic background, lead to increased positive selection (35, 36). However, in contrast to CD5⁻/⁻ mice, DP thymocytes of CBL⁻/⁻ mice have elevated TCR levels due to reduced TCR degradation and increased TCR recycling (37, 38). Thus, increased TCR reactivity in CBL⁻/⁻ DP thymocytes could essentially reflects the increased abundance of the TCR at the plasma membrane. This phenotype might mask another function of CBL. Indeed, considering that the interaction between CBL and CD5 depends on TCR stimulation, the increased TCR responses observed in CD5 deficient mouse could reflect a specific role of CBL strictly dependent on TCR engagement. Hence, two mechanisms of TCR signaling regulation involving CBL could coexist (Figure 2A). One where CBL, independently of CD5, regulates the constitutive TCR pool at the surface of DP thymocytes and another one, triggered by the TCR stimulation, relocating a fraction of CBL molecules to the synapse via CD5 and promoting its inhibitory activity (ubiquitination) in this particular cellular localization. In this molecular context, specific effectors of the proximal TCR signaling pathway could be negatively controlled by CBL.

Hence, both in thymocytes and in mature T cells, CBL molecules are possible molecular mediators of CD5 inhibition of TCR signaling (Figure 2B).

## CONTRIBUTIONS OF UBASH3A/B MOLECULES TO CD5 INHIBITION

Other molecules than CD5 associated with both CBL and CBLB in TCR stimulated mature T cells (24). Among them, the Ubiquitin-associated and SH3 domain-containing protein A and B (UBASH3A, UBASH3B also known as STS-2 and STS-1) have been associated with negative regulation of the TCR signaling pathway (39) and might therefore participate in CD5 inhibition.

Association of CBL with UBASH3A was detected in unstimulated thymocytes and mature T cells and remained unchanged upon TCR stimulation (Figure 1). In contrast, UBASH3B was associated with CBL only upon TCR stimulation and this recruitment correlated with that of CBLB. This suggests preferential associations of CBL with UBASH3A and CBLB with UBASH3B. In support of this statement, the expression pattern of
<figure><img src="image_3.png" /></figure>

**FIGURE 1** | Association of selected proteins with CBL in thymocytes and mature T cells. Mature CD4⁺ T cells and thymocytes from wild-type (WT) and gene-targeted mice expressing One-STRIP-tag at the carboxyl-terminus of endogenous CBL (CBL-OST) were left unstimulated (unstim.) or stimulated for 30 s (stim.) with anti-CD3 plus anti-CD4 antibodies and subsequently lysed. Protein lysates were subjected to OST affinity purification coupled to mass spectrometry analysis (AP-MS) (24, 34). For each sample, protein intensities were log transformed and normalized by the sample median intensity. Intensities were then averaged across technical replicates and missing values imputed by values simulating noise around the detection limit. After missing values imputation, log-transformed intensities from WT and CBL-OST cells were compared using a two-sided Welch t-test (symbols used according to the t-test P-value: N.S., *P* > 0.05; \* *P* ≤ 0.05; \*\* *P* ≤ 0.01; \*\*\* *P* ≤ 0.001). Intensities were divided by the minimum intensity across all intensities represented to ensure that all log-transformed values were positive. Data used for mature CD4⁺ T cells are from Voisinne et al. (24) (NA, non-applicable).

UBASH3A and UBASH3B proteins in alpha/beta T cells is similar to that of CBL and CBLB, respectively (39) (www.immgen.org). Hence, UBASH3A is highly expressed in DP thymocytes whereas expression of UBASH3B starts in single positive (SP) thymocytes.

Both UBASH3 molecules exert phosphatase activities and bind ubiquitinated proteins though their UBA domains (40, 41). When both molecules are inactivated, mature T cells showed an enhanced capacity to proliferate and secrete cytokines, a phenotype reminiscent of those observed with CD5 and CBLB deficient mice (39). In addition, in dually UBASH3 deficient mouse, TCR stimulation triggers increased tyrosine phosphorylation and ubiquitination of signaling effectors (39). The simultaneous increase of these post-translational modifications could be due to the fact that the activation-deactivation sequence of specific effectors is stopped at a stage where they have been phosphorylated by tyrosine kinases,

ubiquitinated by CBL molecules but subsequently improperly dephosphorylated or targeted for degradation as they should when UBASH molecules bind to ubiquitin. As confirmed by recent studies, one of the first targets of this regulation is ZAP-70 (42, 43). In this context, it is possible that CD5 allows molecular cooperativity between CBL and UBASH3 molecules to terminate TCR induced signaling by dampening the activity of ZAP-70 kinase and by contributing to its degradation (Figure 2B).

## CD5-MEDIATED REGULATION OF CSK

Another potential mediator of the CD5 inhibition that was also detected with both CBL and CBLB after TCR engagement is the tyrosine kinase CSK. The recruitment of CD5 and CSK to both CBL molecules was correlated indicating a possible physical
<figure><img src="image_4.png" /></figure>

**FIGURE 2** | (A) A model of signaling in double positive (DP) thymocytes from wild-type, CBL<sup>-/-</sup> and CD5<sup>-/-</sup> mice. Prior selection (left), constitutive TCR internalization, recycling and degradation are regulated by CBL. CD5 is not involved in these processes but CD5 protein level is transcriptionally controlled by weak constitutive TCR signaling (green arrow). In the absence of CBL, surface TCR concentration increases which enhances transcription of CD5. Surface TCR concentration is unaffected in CD5 deficient cells and remains controlled by CBL. During selection (right), CBL associates with CD5 within the immunological synapse (IS) to negatively control TCR signaling. In the absence of CBL, TCRs accumulate at the cell surface leading to increased TCR signaling. The inhibition of TCR signaling by CD5 is impaired in the absence of CBL. In CD5 deficient cells, recruitment of CBL to the immunological synapse (IS) is impaired which leads to enhanced TCR signaling. (cTEC: Cortical thymic epithelial cell) (B) A model of CD5 signaling in thymocytes and mature T cells. Upon TCR engagement, LCK phosphorylates the CD3 chains and CD5 (blue arrows). Phosphorylation of CD5 allows interactions of inhibitory molecules such as CBL and UBASH3 proteins triggering post-translation modifications (ubiquitination, dephosphorylation) of positive effectors (ZAP70, PI3K) involved in the proximal TCR signaling pathway. The global negative signal mediated by CD5 is symbolized by the inhibitory red line. In thymocytes, CBLB and UBASH3B expressions are undetectable, CD5 associated only with CBL and UBASH3A. The PI3K interacts with CBL in thymocytes and in peripheral T cells. PI3K regulation by ubiquitination is essentially mediated by CBLB. (C) An alternative model of CD5 signaling involving CSK. In quiescent T cells CSK interacts with PAG to negatively control LCK (1). Upon TCR engagement LCK phosphorylates CD5 (2). CSK molecules associated with phosphorylated CD5 localized into the IS. CD5-associated CSK phosphorylates the inhibitory tyrosine residue of LCK thereby reducing the magnitude of TCR signaling (3). Panel (A) was modified from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License. http://smart.servier.com/.

association between them. This association was confirmed by co-
immunoprecipitation of CSK with CD5 upon TCR stimulation
(24). CSK has been shown to control the activity of Src kinases by
phosphorylating their C-terminal tyrosine residue (44). In turn,
CSK activity depends on its association with the transmembrane
adaptor PAG (45, 46). In this context, CD5 ligation was shown
to induce the phosphorylation of the Src kinase Fyn at its C-
terminal inhibitory residue and attenuate its activity (14). To
explain this observation, it has been proposed that CD5 could
interfere with the disassembly of the CSK-PAG complexes during
T cell activation. However, in contrast to CSK and CD5, PAG

was not identified as a binding partner of either CBL or CBLB in
TCR stimulated mature T cells. This suggest that different pools
of CSK are present in T cells, within different protein complexes.
Moreover, a recent study has demonstrated that PAG-regulated
TCR signaling is essentially active in effector T cells (47). Thus,
it is conceivable that the facilitation of CSK recruitment to
the synapse could operate through alternative transmembrane
adaptors, and possibly directly with CD5, depending of the
activation state of T cells. An attractive model could be that
CD5 binds to CSK through its SH2 domain. In this setting, the
interaction between CD5 and CSK, induced by TCR stimulation,
could participate in a negative feedback loop by reducing the activity of Src kinase recruited to the synapse (Figure 2C).

## CD5 AND IMMUNOTHERAPY

Accumulated knowledge on immunomodulatory properties of CD5 positions this receptor as a putative checkpoint inhibitor, potentially useful in the context of immunotherapies. In this context, one way to harness the inhibitory functions of CD5 would be the development of anti-CD5 monoclonal antibodies (mAb) having diverse functional properties. Thus, mAb with the ability to sequester the receptor away from the T cell synapse could be useful to reduce CD5 inhibitory signaling and increase T cell responses against tumors. Alternatively, anti-CD5 mAbs enhancing the inhibitory role of the receptor could help improve autoimmune diseases by reducing effector functions of autoreactive T cells.

Prior the emergence of antibody-based cancer treatments, results of clinical trials using anti-CD5 mAb have established moderated benefit in patients with chronic lymphocyte leukemia or cutaneous T-cell lymphomas (48, 49). With the recent advances in immunotherapies, experimental protocols have evolved and critical factors have been identified to improve treatment efficacies. For example, manipulation of antibody structure to avoid rapid clearance and immune response against the therapeutic mAb is one of the issue that could be investigated with CD5. Also, evaluation of biological effects provided by combination with other antibodies in a broader spectrum of malignancies could reveal CD5 as a potent target to control cancer.

However, immunotherapy strategies targeting CD5 should be the object of cautious attention. Indeed, as CD5 is expressed in all T cell subsets and on B-1a B cells, in vivo administration of CD5 specific antibodies will result in the sum of individual cell type responses. For example, it has been shown that generation of induced Treg (iTreg) cells is altered among CD5 low or CD5 deficient T cell populations (50). It is therefore likely that inhibition of CD5 would simultaneously reduce iTreg cell

number and activate effector functions on conventional T cells, thereby increasing T cell reactivity against self and potentiating auto-immune disorders. In addition and as proposed by studies using a mouse expressing a serine-truncated CD5 form, signaling of the receptor can also affect T cell differentiation toward specific Th subsets (51). Therefore, all these parameters must be taken into consideration in order to avoid the onset of undesirable reactions resulting from complex global effects.

## CONCLUDING REMARKS

Overall, it appears that distinct molecular mechanisms remain possible to explain the negative regulation of TCR signaling exerted by CD5 in thymocytes, naïve and effector T cells. As illustrated by the different signaling models presented here, CD5 could act as a scaffold coordinating the action of CBL, UBASH3 and CSK molecules within the immunological synapse. In conclusion, CD5 and the identified effectors involved in the same signaling pathway offer great potential for the development of new drugs. However, complexity of the molecular relationships and difficulties to predict perturbations of the system must be taken into account prior to the design of new therapeutic strategies.

## AUTHOR CONTRIBUTIONS

GV, AGP, and RR generated, analyzed the data and wrote the manuscript.

## ACKNOWLEDGMENTS

We thank Bernard Malissen and Renaud Lesourne for discussion. This work was supported by CNRS, INSERM, Agence Nationale de la Recherche (LymphoScan project to RR), the Investissement d'Avenir program ProFI (Proteomics French Infrastructure project; ANR-10-INBS-08) and PHENOMIN (French National Infrastructure for Mouse Phenogenomics), Région Midi-Pyrénées.

## REFERENCES

1. Schraven B, Kalinke U. CD28 superagonists: what makes the difference in humans? *Immunity* (2008) 28:591–5. doi: 10.1016/j.immuni.2008.04.003

2. Azzam HS, Grinberg A, Lui K, Shen H, Shores EW, Love PE. CD5 expression is developmentally regulated by T cell receptor (TCR) signals and TCR avidity. *J Exp Med.* (1998) 188:2301–11. doi: 10.1084/jem.188.12.2301

3. Biancone L, Bowen MA, Lim A, Aruffo A, Andres G, Stamenkovic I. Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. *J Exp Med.* (1996) 184:811–9. doi: 10.1084/jem.184.3.811

4. Mandl JN, Monteiro JP, Vrisekoop N, Germain RN. T cell-positive selection uses self-ligand binding strength to optimize repertoire recognition of foreign antigens. *Immunity* (2013) 38:263–74. doi: 10.1016/j.immuni.2012.09.011

5. Persaud SP, Parker CR, Lo WL, Weber KS, Allen PM. Intrinsic CD4⁺ T cell sensitivity and response to a pathogen are set and sustained by avidity for thymic and peripheral complexes of self peptide and MHC. *Nat Immunol.* (2014) 15:266–74. doi: 10.1038/ni.2822

6. Tarakhovsky A, Kanner SB, Hombach J, Ledbetter JA, Muller W, Killeen N, et al. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. *Science* (1995) 269:535–7. doi: 10.1126/science.7542801

7. Azzam HS, DeJarnette JB, Huang K, Emmons R, Park CS, Sommers CL, et al. Fine tuning of TCR signaling by CD5. *J Immunol.* (2001) 166:5464–72. doi: 10.4049/jimmunol.166.9.5464

8. Pena-Rossi C, Zuckerman LA, Strong J, Kwan J, Ferris W, Chan S, et al. Negative regulation of CD4 lineage development and responses by CD5. *J Immunol.* (1999) 163:6494–501.

9. Fulton RB, Hamilton SE, Xing Y, Best JA, Goldrath AW, Hogquist KA, et al. The TCR's sensitivity to self peptide-MHC dictates the ability of naïve CD8 T cells to respond to foreign antigens. *Nat Immunol.* (2014) 16:107–17. doi: 10.1038/ni.3043

10. Orta-Mascaro M, Consuegra-Fernandez M, Carreras E, Roncagalli R, Carreras-Sureda A, Alvarez P, et al. CD6 modulates thymocyte selection and peripheral T cell homeostasis. *J Exp Med.* (2016) 213:1387–97. doi: 10.1084/jem.20151785
11. Van de Velde H, von Hoegen I, Luo W, Parnes JR, Thielemans K. The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. *Nature* (1991) 351:662–5. doi: 10.1038/351662a0

12. Calvo J, Places L, Padilla O, Vila JM, Vives J, Bowen MA, et al. Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand. *Eur J Immunol.* (1999) 29:2119–29. doi: 10.1002/(SICI)1521-4141(199907)29:07<2119::AID-IMMU2119>3.0.CO;2-F

13. Brown MH, Lacey E. A ligand for CD5 is CD5. *J Immunol* (2010) 185:6068–74. doi: 10.4049/jimmunol.0903823

14. Bamberger M, Santos AM, Goncalves CM, Oliveira MI, James JR, Moreira A, et al. A new pathway of CD5 glycoprotein-mediated T cell inhibition dependent on inhibitory phosphorylation of Fyn kinase. *J Biol Chem.* (2011) 286:30324–36. doi: 10.1074/jbc.M111.230102

15. Davies AA, Ley SC, Crumpton MJ. CD5 is phosphorylated on tyrosine after stimulation of the T-cell antigen receptor complex. *Proc Natl Acad Sci USA.* (1992) 89:6368–72. doi: 10.1073/pnas.89.14.6368

16. Brossard C, Semichon M, Trautmann A, Bismuth G. CD5 inhibits signaling at the immunological synapse without impairing its formation. *J Immunol.* (2003) 170:4623–9. doi: 10.4049/jimmunol.170.9.4623

17. Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB. CD5 negatively regulates the T-cell antigen receptor signal transduction pathway, involvement of SH2-containing phosphotyrosine phosphatase SHP-1. *Mol Cell Biol.* (1999) 19:2903–12. doi: 10.1128/MCB.19.4.2903

18. Dennehy KM, Broszeit R, Ferris WF, Beyers AD. Thymocyte activation induces the association of the proto-oncprotein c-cbl and ras GTPase-activating protein with CD5. *Eur J Immunol.* (1998) 28:1617–25. doi: 10.1002/(SICI)1521-4141(199805)28:05<1617::AID-IMMU1617>3.0.CO;2-T

19. Gary-Gouy H, Bruhns P, Schmitt C, Dalloul A, Daeron M, Bismuth G. The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling. *J Biol Chem.* (2000) 275:548–56. doi: 10.1074/jbc.275.1.548

20. Dennehy KM, Broszeit R, Garnett D, Durrheim GA, Spruyt LL, Beyers AD. Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5. *Eur J Immunol.* (1997) 27:679–86. doi: 10.1002/eji.1830270316

21. Raman C, Kuo A, Deshane J, Litchfield DW, Kimberly RP. Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5. *J Biol Chem.* (1998) 273:19183–9. doi: 10.1074/jbc.C273.30.19183

22. Axtell RC, Xu L, Barnum SR, Raman C. CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis, protection is associated with diminished populations of IL-17-expressing T cells in the central nervous system. *J Immunol.* (2006) 177:8542–9. doi: 10.4049/jimmunol.177.12.8542

23. Sestero CM, McGuire DJ, De Sarno P, Brantley EC, Soldevila G, Axtell RC, et al. CD5-dependent CK2 activation pathway regulates threshold for T cell anergy. *J Immunol.* (2012) 189:2918–30. doi: 10.4049/jimmunol.1200065

24. Voisinne G, Garcia-Blesa A, Chaoui K, Fiore F, Bergot E, Girard L, et al. Co-recruitment analysis of the CBL and CBLB signalosomes in primary T cells identifies CD5 as a key regulator of TCR-induced ubiquitylation. *Mol Syst Biol.* (2016) 12:876. doi: 10.15252/msb.20166837

25. Caron E, Roncagalli R, Hase T, Wolski WE, Choi M, Menoita MG, et al. Precise temporal profiling of signaling complexes in primary cells using SWATH mass spectrometry. *Cell Rep.* (2017) 18:3219–26. doi: 10.1016/j.celrep.2017.03.019

26. Huang F, Gu H. Negative regulation of lymphocyte development and function by the Cbl family of proteins. *Immunol Rev.* (2008) 224:229–38. doi: 10.1111/j.1600-065X.2008.00655.x

27. Wang HY, Altman Y, Fang D, Elly C, Dai Y, Shao Y, et al. Cbl promotes ubiquitination of the T cell receptor zeta through an adaptor function of Zap-70. *J Biol Chem.* (2001) 276:26004–11. doi: 10.1074/jbc.M010738200

28. Thien CB, Bowtell DD, Langdon WY. Perturbed regulation of ZAP-70 and sustained tyrosine phosphorylation of LAT and SLP-76 in c-Cbl-deficient thymocytes. *J Immunol.* (1999) 162:7133–9.

29. Thien CB, Langdon WY. c-Cbl and Cbl-b ubiquitin ligases, substrate diversity and the negative regulation of signalling responses. *Biochem J.* (2005) 391:153–66. doi: 10.1042/BJ20050892

30. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, Hu RJ, et al. Cbl-b regulates the CD28 dependence of T-cell activation. *Nature* (2000) 403:216–20. doi: 10.1038/35003235

31. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki TA, Oliveira-dos-Santos, A, et al. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. *Nature* (2000) 403:211–16. doi: 10.1038/35003228

32. Fang D, Liu YC. Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells. *Nat Immunol.* (2001) 2:870–5. doi: 10.1038/ni0901-870

33. Rorsman C, Tsioupekou M, Heldin CH, Lennartsson J. The ubiquitin ligases c-Cbl and Cbl-b negatively regulate platelet-derived growth factor (PDGF) BB-induced chemotaxis by affecting PDGF receptor beta (PDGFRbeta) internalization and signaling. *J Biol Chem.* (2016) 291:11608–18. doi: 10.1074/jbc.M115.705814

34. Roncagalli R, Hauri S, Fiore F, Liang Y, Chen Z, Sansoni A, et al. Quantitative proteomics analysis of signalosome dynamics in primary T cells identifies the surface receptor CD6 as a Lat adaptor-independent TCR signaling hub. *Nat Immunol.* (2014) 15:384–92. doi: 10.1038/ni.2843

35. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, Thien CB, et al. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. *Mol Cell Biol.* (1998) 18:4872–82. doi: 10.1128/MCB.18.8.4872

36. Naramura M, Kole HK, Hu RJ, Gu H. Altered thymic positive selection and intracellular signals in Cbl-deficient mice. *Proc Natl Acad Sci USA.* (1998) 95:15547–52. doi: 10.1073/pnas.95.26.15547

37. Naramura M, Jang IK, Kole H, Huang F, Haines D, Gu H. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. *Nat Immunol.* (2002) 3:1192–9. doi: 10.1038/ni855

38. Myers MD, Sosinowski T, Dragone LL, White C, Band H, Gu H, et al. Src-like adaptor protein regulates TCR expression on thymocytes by linking the ubiquitin ligase c-Cbl to the TCR complex. *Nat Immunol.* (2006) 7:57–66. doi: 10.1038/ni1291

39. Carpino N, Turner S, Mekala D, Takahashi Y, Zang H, Geiger TL, et al. Regulation of ZAP-70 activation and TCR signaling by two related proteins, Sts-1 and Sts-2. *Immunity* (2004) 20:37–46. doi: 10.1016/S1074-7613(03)00351-0

40. Carpino N, Chen Y, Nassar N, Oh HW. The Sts proteins target tyrosine phosphorylated, ubiquitinated proteins within TCR signaling pathways. *Mol Immunol.* (2009) 46:3224–31. doi: 10.1016/j.molimm.2009.08.015

41. Hoeller D, Crosetto N, Blagoev B, Raiborg C, Tikkanen R, Wagner S, et al. Regulation of ubiquitin-binding proteins by monoubiquitination. *Nat Cell Biol.* (2006) 8:163–9. doi: 10.1038/ncb1354

42. Yang M, Chen T, Li X, Yu Z, Tang S, Wang C, et al. K33-linked polyubiquitination of Zap70 by Nrdp1 controls CD8⁺ T cell activation. *Nat Immunol.* (2015) 16:1253–62. doi: 10.1038/ni.3258

43. Hu H, Wang H, Xiao Y, Jin J, Chang JH, Zou Q, et al. Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination. *J Exp Med.* (2016) 213:399–414. doi: 10.1084/jem.20151426

44. Okada M, Nada S, Yamanashi Y, Yamamoto T, Nakagawa H. CSK, a protein-tyrosine kinase involved in regulation of src family kinases. *J Biol Chem.* (1991) 266:24249–52.

45. Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. *J Exp Med.* (2000) 191:1591–604. doi: 10.1084/jem.191.9.1591

46. Davidson D, Bakinowski M, Thomas ML, Horejsi V, Veillette A. Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. *Mol Cell Biol.* (2003) 23:2017–28. doi: 10.1128/MCB.23.6.2017-2028.2003

47. Davidson D, Zhong MC, Pandolfi PP, Bolland S, Xavier RJ, Seed B, et al. The Csk-associated adaptor PAG inhibits effector T cell activation in cooperation with phosphatase PTPN22 and dok adaptors. *Cell Rep.* (2016) 17:2776–88. doi: 10.1016/j.celrep.2016.11.035

48. Dillman RO, Shawler DL, Dillman JB, Royston I. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. *J Clin Oncol.* (1984) 2:881–91. doi: 10.1200/JCO.1984.2.8.881
49. Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. *Clin Cancer Res.* (1998) 4:2691–700.

50. Henderson JG, Opejin A, Jones A, Gross C, Hawiger D. CD5 instructs extrathymic regulatory T cell development in response to self and tolerizing antigens. *Immunity* (2015) 42:471–83. doi: 10.1016/j.immuni.2015.02.010

51. McGuire DJ, Rowse AL, Li H, Peng BJ, Sestero CM, Cashman KS, et al. CD5 enhances Th17-cell differentiation by regulating IFN-gamma response and RORgammat localization. *Eur J Immunol.* (2014) 44:1137–42. doi: 10.1002/eji.201343998

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Voisinne. Gonzalez de Peredo and Roncagalli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.